STOCK TITAN

Pheton Holdings (PTHL) furnishes unaudited 2024-2025 interim statements

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Pheton Holdings Ltd is furnishing unaudited interim condensed consolidated financial statements for the six months ended June 30, 2025, in a report as a foreign private issuer. These statements, attached as Exhibit 99.1, cover the six-month periods ended June 30, 2024 and 2025 and provide a detailed view of the company’s mid-year financial position and operating results.

Positive

  • None.

Negative

  • None.

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of December 2025

 

Commission File Number: 001-42263

 

Pheton Holdings Ltd.

 

Room 306, NET Building,

Hong Jun Ying South Road, Chaoyang District,

Beijing, China.

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F       Form 40-F

 

 

 

 

 

EXPLANATORY NOTE

 

Pheton Holdings Ltd, a Cayman Islands company (the “Company”), is furnishing its unaudited interim condensed consolidated financial statements and notes for the six months ended June 30, 2025. The financial statements and notes are attached as Exhibit 99.1 to this report.

 

1

 

 

EXHIBIT INDEX

 

Exhibit No.   Description
99.1   Unaudited Interim Condensed Consolidated Financial Statements for the Six Months Ended June 30, 2024 and 2025
101. INS   Inline XBRL Instance Document
101.SCH   Inline XBRL Taxonomy Extension Schema Document
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Pheton Holdings Ltd
     
Date: December 16, 2025 By: /s/ Jianfei Zhang
  Name:  Jianfei Zhang
  Title:

Chief Executive Officer and Chairman of the Board of Directors 

 

3

 

FAQ

What did Pheton Holdings Ltd (PTHL) submit in this SEC report?

Pheton Holdings Ltd submitted unaudited interim condensed consolidated financial statements and notes for the six months ended June 30, 2025, furnished as Exhibit 99.1.

Which periods do the interim financial statements of Pheton Holdings (PTHL) cover?

The interim financial statements cover the six months ended June 30, 2024 and 2025, as described in the exhibit index.

Are the Pheton Holdings (PTHL) interim financial statements audited?

No. The report specifies that Pheton Holdings is furnishing unaudited interim condensed consolidated financial statements for the six-month period.

Where can investors find the detailed Pheton Holdings (PTHL) financial tables?

The detailed financial information is contained in Exhibit 99.1, titled “Unaudited Interim Condensed Consolidated Financial Statements for the Six Months Ended June 30, 2024 and 2025,” and related Inline XBRL exhibits.

What type of issuer is Pheton Holdings Ltd (PTHL) under U.S. rules?

Pheton Holdings Ltd is identified as a foreign private issuer reporting under the Securities Exchange Act of 1934.

What XBRL data does Pheton Holdings (PTHL) provide with this submission?

The filing includes Inline XBRL exhibits such as the instance document, taxonomy extension schema, calculation, definition, label, and presentation linkbase documents, plus a cover page interactive data file.

Pheton Holdings

NASDAQ:PTHL

PTHL Rankings

PTHL Latest News

PTHL Latest SEC Filings

PTHL Stock Data

15.38M
7.45M
29.35%
0.12%
6.9%
Medical Devices
Healthcare
Link
China
Beijing